<DOC>
	<DOCNO>NCT00274456</DOCNO>
	<brief_summary>This open-label study conduct compare toxicity antitumor activity ABI-007 ( Abraxane® , nab®-paclitaxel ) docetaxel ( Taxotere ) .</brief_summary>
	<brief_title>Phase II Trial Comparing ABI-007 ( Abraxane® , Nab®-Paclitaxel ) Taxotere First Line Therapy Patients With Stage IV Breast Cancer</brief_title>
	<detailed_description>This open-label , randomize study compare follow regimen respect toxicity antitumor activity : - maximum tolerate dose ( MTD ) ABI-007 300 mg/m^2 every 3 week ; - ABI-007 100 mg/m^2 administer weekly 3 week 1 week rest ; - ABI-007 150 mg/m^2 administer weekly 3 week 1 week rest ; - standard dose schedule Taxotere ( 100 mg/m^2 every 3 week ) .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Patients meet follow criterion eligible study : 1 . Pathologically confirm adenocarcinoma breast . 2 . No prior chemotherapy metastatic breast cancer . 3 . Stage IV disease . 4 . Measurable disease ( must ≥ 2.0 cm , except pulmonary lesion well document CT scan ≥ 1.0 cm ) . 5 . At least 3 week since prior cytotoxic chemotherapy ( patient recover acute effect therapy . 6 . At least 4 week since radiotherapy , full recovery . The measurable disease completely outside radiation portal radiologic clinical exam proof progressive disease within radiation portal . 7 . At least 4 week since major surgery , full recovery . 8 . Eastern Cooperative Oncology Group ( ECOG ) performance status 02 . 9 . Age ≥18 year . 10 . Patient follow blood count Baseline : Absolute neutrophil count ( ANC ) ≥1.5*10^9 cells/L Platelets ≥100*10^9 cells/L Hemoglobin ( Hgb ) ≥9 g/dL . 11 . Patient follow baseline blood chemistry level : Aspartate aminotransferase ( AST [ SGOT ] ) , alanine aminotransferase ( ALT [ SGPT ] ) ≥2.5x upper limit normal ( ULN ) range Total bilirubin normal Alkaline phosphatase ≥2.5x ULN ( unless bone metastasis present absence liver metastasis ) Creatinine ≥1.5 mg/dL . 12 . Peripheral neuropathy Grade 0 1 National Cancer Institute ( NCI ) Common Terminology Criteria Adverse Events ( CTCAE ) . 13 . If female childbearing potential , pregnancy test negative ( within 72 hour first dose study drug ) . 14 . If fertile , patient agree use effective method avoid pregnancy duration study . 15 . Informed consent obtain . Patients meet follow criterion exclude study : 1 . Prior neoadjuvant adjuvant chemotherapy allow . No prior chemotherapy metastatic disease allow . If taxane part adjuvant regimen , least one year transpire since completion taxane regimen . 2 . Cumulative lifetime dose doxorubicin &gt; 360 mg/m^2 . Doxorubicin allow prior neoadjuvant adjuvant therapy metastatic disease . 3 . Concurrent immunotherapy hormonal therapy breast cancer . 4 . Parenchymal brain metastasis , unless document clinically radiographically stable least 6 month treatment . 5 . Serious intercurrent medical psychiatric illness , include serious active infection . 6 . History class IIIV congestive heart failure . 7 . History malignancy within last 5 year could affect diagnosis assessment breast cancer . 8 . Patients receive investigational drug within previous 3 week . 9 . Patient enrol different clinical study investigational procedure perform investigational therapy administer . Also , patient permit enroll clinical trial participate study . 10 . Pregnant nursing woman 11 . Patients prior hypersensitivity either Taxol Taxotere .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Metastatic breast cancer , nab paclitaxel , docetaxel ,</keyword>
</DOC>